As per the agreement, Takeda Brazil will take over Multilab for BRL500m upfront and up to BRL40m in additional future milestone payments to the owners of Multilab. The other financial conditions were not revealed.
Takeda Emerging Markets Commercial Operations head Jostein Davidsen said, "Takeda has ambitious plans for growth in emerging markets. Brazil is our second largest emerging market after Russia/CIS in terms of revenues and the acquisition of Multilab is a clear signal of our intention to become a significant player both in Brazil and other high-growth markets."
The transaction is expected to be finalized by the end of the second quarter of its fiscal year 2012.
Multilab is a mid-sized pharmaceutical company. Its business consists of branded generics and OTC pharmaceutical products.